Compare POWL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POWL | BLTE |
|---|---|---|
| Founded | 1947 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.0B |
| IPO Year | 1995 | 2021 |
| Metric | POWL | BLTE |
|---|---|---|
| Price | $193.30 | $154.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $280.00 | $228.89 |
| AVG Volume (30 Days) | ★ 470.9K | 117.0K |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $448,716,000.00 | N/A |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $24.54 | N/A |
| P/E Ratio | $49.68 | ★ N/A |
| Revenue Growth | ★ 13.34 | N/A |
| 52 Week Low | $167.31 | $78.71 |
| 52 Week High | $612.50 | $200.00 |
| Indicator | POWL | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 39.00 |
| Support Level | $180.98 | $145.95 |
| Resistance Level | $219.27 | $161.10 |
| Average True Range (ATR) | 7.44 | 5.38 |
| MACD | 1.43 | -1.98 |
| Stochastic Oscillator | 48.22 | 16.73 |
Powell Industries Inc is a United States-based company that develops, designs, manufactures, and services custom-engineered equipment and systems for electrical energy distribution, control, and monitoring. The company's principal products comprise integrated power control room substations, custom-engineered modules, electrical houses, traditional and arc-resistant distribution switchgear and control gear, and so on. These products are applied in oil and gas refining, offshore oil and gas production, petrochemical, pipeline, terminal, mining and metals, light-rail traction power, electric utility, pulp and paper, and other heavy industrial markets. The company generates the majority of its sales from the United States, and the rest from Canada, Europe, Asia Pacific, and other regions.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.